TTFields significantly inhibited the growth of the glioma cells to a degree beyond that of Withaferin A or TTFields alone. The interaction of the Withaferin A and TTFields on glioma cells was found to be synergistic in nature (p < 0.01, n = 3 experiments). These findings were validated by both bioluminescence and hemocytometric measurements. The combination of Withaferin A with TTFields represents a novel approach to treat GBM in a manner that is likely better than either treatment alone and that is synergistic.
Introduction
Glioblastoma (GBM) is the most common yet deadliest form of primary brain cancer (median survival time: 15-17 months; 5-year survival: 5-10%) [1, 2] . Given its aggressive nature, current interventions consist of equally aggressive surgical resection and subsequent radio-and chemotherapy. Because the cancer is highly heterogeneous, these standardized but non-specific therapies are often ineffective [2] . To establish progress against GBM, new, unorthodox therapies must be pursued.
Treatment of cancers by tumor treating fields (TTFields) is a novel, validated therapy that may represent an additional paradigm in anti-cancer treatments [3] . While not definitively established, the mechanism of anti-cancer action by TTFields most likely rests upon the property that actin filaments have intrinsic dipole moments [4] . By forcing actin filaments to align along electric field lines through the imposition of a TTField, one interrupts the functionality of the mitotic spindle in actively dividing cells [5] , thereby disrupting the actin-based cytoskeleton supporting the mitotic spindles [4] . Such stress on the spindles perturbs cellular division [4] . Numerous proof of concept experiments as well as relevant technological developments have occurred over the last 10 years [4] , culminating in the approval by the Food and Drug Administration (FDA) of a commercial, clinical TTField device (Optune ® , Novocure Ltd., Jersey, UK) for the treatment of newly diagnosed glioblastoma [6] .
There have been clinical investigations into combination therapies. Treatment by TTFields in combination with temozolomide has resulted in significant extension of overall survival in glioblastoma patients [7] . Cases of combination therapy of TTFields with bevacizumab have been reported [8] . Preliminary findings suggests that the interaction between TTField and either temozolomide or bevacizumab are additive as opposed to synergistic but the data requires further elucidation. For detailed mathematical definition of additivity versus synergy, please see Fang et al. [9] .
Withaferin A is a steroidal lactone that originates from the roots and leaves of the winter cherry plant (Withania somnifera) [10] . Recently, we demonstrated, for the first time, the effectiveness of Withaferin A in inhibiting the growth of human gliomas in cell culture and in preclinical murine models of orthotopic GBM [11] . A unified insight into Withaferin A's action is still forthcoming, but researchers have shown it to affect expression and activity of numerous transcription factors such as NF-κB and Sp1 [12, 13] . Like TTFields, these factors impact the dynamics of cytoskeletal assembly and disassembly [14] [15] [16] . Thus, it is unsurprising that Withaferin A is associated with disruption of vimentin/actin assembly and cytoskeletal organization [17] [18] [19] . We thus hypothesized that the combination of TTFields and Withaferin A, the main component of an Ayurvedic natural product, retards glioblastoma proliferation in a synergistic manner. We report here the effects of the combination therapy approach on three glioblastoma cell lines: U87-MG, GBM2 and GBM39. All are humanderived and have functional, morphological and genomic variations that represent the heterogeneity of gliomas. The current investigation builds upon a previous study [11] in which we looked at the role of natural products in advancing anti-glioblastoma therapies.
Materials and methods

Cell culture studies
Two patient-derived GBM lines (GBM2 [20] , GBM39 [21] ) and one commercially available human GBM cell line (U87-MG from ATCC, Manassas, VA, USA) were used for our studies. The breast adenocarcinoma cell line, MDA-MB-231, was also purchased from ATCC. GBM2 originated from the Stanford University Medical Hospital and was obtained for research purposes after approval from the University's Internal Review Board (IRB-28612). GBM39 was a gift from Dr. Paul Mischel (Ludwig Institute for Cancer Research, University of California at San Diego). Details of cell culture conditions summarized in Supplemental Method One.
Seeding of cells onto thermanox cover slips for TTField experiments
Approximately 50,000 single cells were seeded onto the center of a 22 mm diameter glass or plastic Nunc Thermanox™ cover slip (ThermoFisher Scientific, Waltham, MA, USA) in 6-well plates. The cells were left to grow on the cover slip for 2-3 days before being transferred to a ceramic dish of an inovitro™ in vitro TTField device (Novocure Inc., Haifa, Israel). Refer to Supplemental Method Two.
In vitro tumor treating field device
A workflow for a typical TTField experiment is summarized in Fig. 1 . Details described in Fig. 1 legend. Cells were grown in the ceramic dishes of the inovitro ™ system for 3-6 days and then trypsinized and counted according to standardized protocols. Refer to Supplemental Method Two for details.
Cell counting assay via hemocytometer
Cell counting methodologies and averaging were achieved by standardized protocols and visualized on a Zeiss PrimoVert benchtop microscope (Dublin, CA, USA). Unless otherwise stated, cell counts were done on trypsinized, single-cell suspensions with a hemocytometer and the median of the four cell-count measurements was calculated and rounded to the nearest integer. Please refer to legend of Supplemental Figure S1 for details.
Bioluminescence imaging
For all bioluminescence work, we used genetically-modified GBM2, GBM39 and U87-MG whereby cells were transfected with lentiviral vectors that expressed either firefly luciferase (for GBM39) or a fusion protein of GFP and firefly luciferase (for GBM2 and U87) [22, 23] . All BLI work done on an IVIS Spectrum (Xenogen Corporation, Alameda, CA). Please refer to legend of Supplemental The cover slips were placed in a 6-well plate and allowed to incubate in a conventional tissue culture incubator (37 °C, 95% air, 5% CO 2 ) overnight. Once cells adhered to the cover slip, an additional 2 mL of media was added to each well. The cells remained on the cover slips for 2-3 days in order to achieve the growth phase, before they were transferred to (B) the wells of an inovitro ™ TTField system ceramic dish. The dishes were pre-filled with 2 mL of media. The ceramic dishes were placed either in (C) base plates that are connected to the power box of the inovitro ™ TTField system and then into a special incubator for the alternating electric current conditions or (D) into a conventional tissue culture incubator (37 °C, 95% air, 5% CO 2 ) for the control samples. The cells were grown for 3-6 days with daily changes of media in both the TTField and control conditions. (E) At the end of this time, the cover slips were placed in 6-well plates and the cells processed for cell counting or for bioluminescence imaging
Purchase of chemical reagents
Unless otherwise stated, all chemicals, including Withaferin A, were purchased either from Selleckchem Inc. (Houston, TX, USA) or Sigma-Aldrich (St. Louis, MO, USA).
Statistical analysis
Treatments of TTFields vs Withaferin A alone as well as combination treatments of TTFields and Withaferin A were assessed for significance of effect through either 2-way analysis of variance (ANOVA) or significance analysis of regression [9, 24] . Generally, 2-way ANOVA's were used to determine synergy of two treatments at fixed concentration for each treatment. Significance analysis of regression was used if one was examining a dose range for one or both treatments. A Poisson regression was then done with factors of log 10 (Withaferin dose), TTFields (on at 4 V/cm vs. off), and their interaction. 2-way ANOVA was performed using the PRISM 7.0 application (GraphPad Software Inc., La Jolla, CA, USA) while Poisson-based regression analysis was completed with the assistance of two biostatisticians. Bonferroni or Dunnet post-hoc corrections were employed to adjust alpha for multiple comparisons.
Modeling of electric fields
Modeling of electric fields in the well of a hypothetical ceramic dish was completed with Comsol 4.2 Multiphysics simulation software (Comsol Multiphysics Inc., Burlington, MA).
Results
TTFields decrease cellular growth and increased sensitivity to doxorubicin in MDA-MB-231 cells
To investigate if the TTField effect could be reproduced between labs [25] , we examined the effect of TTFields (frequency 150 kHz) on growth patterns of a breast carcinoma cell line (MDA-MB-231). Cellular counts were significantly reduced (n = 3 measurements per time point, p < 0.001) when compared to MDA-MB-231 cells grown without the presence of TTFields (Supplemental Figure  S1A) .
To examine if an applied TTField could sensitize cancer cells to chemotherapeutic agents, we did a dose response study of MDA-MB-231 cellular growth to escalating concentrations of doxorubicin (Supplemental Figure S1B ) in the absence of TTFields where an IC 50 of 0.31 µM for doxorubicin was determined. The application of TTFields (4 V/cm, 200 kHz) consistently decreased MDA-MB-231 cell number for all concentrations of doxorubicin that were studied. These studies verified previous findings [25] and were important to do prior to moving on to studies with GBM cell lines.
Reduced cell proliferation due to TTFields is apparent in several human-derived glioma cell lines
The study shown in Supplemental Figure S1 was extended to three different human-derived, glioma cell lines: GBM2, GBM39 and U87-MG. For all three cell lines, the application of a TTField (4 V/cm) led to a progressive and significant decline (p < 0.0001, TTField vs control for GBM2 and U87-MG; p < 0.02 for GBM39; n = 3 samples per time point for all) in cellular growth (Fig. 2a-c ) when compared to non-TTField controls. The largest differences occurred with U87-MG.
Synergistic inhibition of glioma proliferation by Withaferin A and TTFields
Withaferin A has been shown to inhibit the growth of several glioma lines at an IC 50 of 250 nM [11] . When U87-MG cells were exposed to 0.1 µM of Withaferin A, no significant loss of cell number (with respect to no treatment controls) was observed at 3 days (Fig. 3a) or 6 days (Fig. 3b ) post treatment. Addition of an alternating electric field (4 V/cm or 2.5 V/cm; 3 and 6 days, respectively) led to significant reduction (at least p < 0.02, TTField vs control, n = 3 samples) in cell number for the TTField samples (Fig. 3a, b) . Addition of 0.1 µM Withaferin A to TTFields led to a further, significant decrease in cell number with respect to TTField alone (p < 0.0001, TTField vs TTField + Withaferin A, n = 3 samples). These findings provide statistical evidence that there was a significant, synergistic interaction between the treatments of TTField (0% reduction alone) and Withaferin A (25% reduction alone) on blocking the proliferation of actively growing, humanderived glioma cells (55% reduction in combination).
We extended the interaction studies between Withaferin A and TTFields to the patient-derived glioma cell lines of U87-MG, GBM39 and GBM2 [11] (Fig. 3c-e) . Also, we examined the effect of several concentrations of Withaferin A (from 0 to 0.3 µM of drug), in the absence and presence of 4 V/cm TTFields at 200 kHz. In all three human glioma cell lines (U87-MG, GBM39, GBM2, Fig. 3c-e) , we found that, in the presence of TTFields, cell culture growth was significantly impeded (p < 0.001, n = 3 samples, TTField vs no TTField) at all doses of Withaferin A tested except for 0 µM (data point on the y-axis). These Poisson-based Analysis of Regression findings of statistically different dose response trends between the absence and the presence of TTFields demonstrates synergistic interactivity between the TTFields and Withaferin A treatments.
Comparative bright field pictographs of corresponding cells further validate the synergy between the two treatments (Fig. 3f) . In the case of treatment with 0.1 µM Withaferin A alone, there was no qualitative difference in the number and size of adherent neurospheres, nor of the patterns in the connective network of the surrounding adherent cells. The application of 200 kHz of TTField alone seemed to disrupt the connective network of the adherent cells around the neurospheres. With the combination of TTFields (4 V/cm) and Withaferin A (0.1 µM), there was a more extensive disruption of the connected network of adherent cells as well as a diminution of size and number of adherent neurospheres. When U87-MG/eGFP-Luc cell's bioluminescence imaging (BLI) activity was assessed with respect to challenge by TTFields (4 V/cm, 200 kHz), Withaferin A (0.1 µM), or both treatments, it was found that the combination of Withaferin A and TTFields reduced BLI activity (with respect to no Withaferin A controls) by 83% (100 vs. 16.9%, TTFields alone compared to TTFields + Withaferin A) while in conditions with no TTFields, BLI activity was reduced by only 49.1% (Supplemental Figure S2 A, B) . A parallel study on GBM39/luc cells also yielded similar bright-field and bioluminescence observations (Supplemental Figure S2 C, D) .
Spatial temperature differential of ceramic dishes does not significantly affect cell growth
Comsol modeling (Supplemental Figure S3 A ) and temperature probing showed that the center of the wells had a mean temperature of 37.6 ± 0.4 °C while the periphery had a significantly (p < 0.00001, paired t-test) lower temperature of 36.7 ± 0.4 °C (Supplemental Figure S3B) . U87-MG cells incubated at 39 °C (but in the absence of a TTField) showed no difference in proliferation when compared to cells incubated at 37 °C (Supplemental Figure S3 C) .
Effect of TTField frequency on U87-MG's cell count and sensitivity to Withaferin A
To examine if phenomena other than the TTField are responsible for decreased cell numbers as well as enhanced sensitivity to Withaferin A, U87-MG cells were exposed to different frequencies in TTFields from 50 to 500 kHz and compared to U87-MG cells not subjected to TTFields (Fig. 4a) . TTField-exposed cells showed no significant difference in cellular population compared to control cells for frequencies of 50, 100 and 500 kHz. However, U87-MG cell numbers were significantly reduced at frequencies of 200 and 400 kHz (p < 0.0001, one-way ANOVA, multiple comparison with respect to no TTField controls, Bonferroni and Dunnett post-hoc corrections). These findings are consistent with findings in the literature for other cancer cell types [4, 26] .
At 50 kHz TTFields, U87-MG cells showed no enhanced sensitivity to Withaferin A (dose range: 0-0.3 µM, Fig. 4b ). In contrast, when lower concentrations of Withaferin A (dose range 0-0.1 µM) were combined with 200 kHz TTFields, cell proliferation was significantly reduced further (p < 0.0001, Fig. 4c ). Previously, it was shown that TTFields alone at this frequency are effective in reducing cell number (Fig. 4a) , as well as being synergistic against U87-MG cell proliferation when combined with a broader range of Withaferin A doses (Fig. 3c) . Taken together, the aforementioned findings would suggest that there is some interaction between the two treatment approaches to enhance U87-MG's susceptibility to lower doses of Withaferin A. At 500 kHz, where neither Withaferin A nor TTFields alone do not significantly affect cell growth (Fig. 4a) , the application of the alternating field at this frequency did significantly (p < 0.0001) sensitize U87-MG cells to low doses of Withaferin A (Fig. 4d) .
Discussion
Our manuscript is the first report on synergistic interaction in therapy between TTFields with the natural product, Withaferin A. TTField application can sensitize glioblastoma stem cells from temozolomide-resistant patients towards temozolomide therapy [7, 27] . Several different TTField combination therapies with numerous cytostatic agents (metformin, mefloquine, ganciclovir, bumetanide, and minocycline) have been studied in glioma cell lines but in no treatment regimen was there more than an additive improvement in efficacy of the cytostatic [28] while statistical analysis in the current study indicated therapeutic synergy with co-treatments of Withaferin A and TTFields.
It is known, that TTFields can stall replication of actively growing cells by disruption of cytoskeletal proteins, such as septin, that participate in the stabilization of the mitotic spindle of dividing cells [29] . Though the mechanisms of action for Withaferin A are most likely multifactorial, there have been reports suggesting that the lactonal steroid acts through disruption of the cytoskeletal framework as well [18, 19] . However more experiments will be needed to determine if this is indeed the reason for the synergistic interaction between Withaferin A and TTFields. Interestingly, combination studies with other mitotic spindle disruptors such as chloroquine [30] or IN-3, [31] revealed data suggesting synergistic, TTField-mediated disruption in glioma proliferation that acts either through multiple disruptions along the mitotic spindle or through several sites of interference throughout the cytoskeletal network supporting the spindle or through both. However the potential by TTFields to alter membrane permeability in cancer cells could in turn alter their sensitivity to anti-cancer drugs.
The FDA has approved the clinical use of TTFields in newly-diagnosed GBM patients [6] with the Optune ® TTField device [5] . Such acceptance of therapy has prompted several lines of investigation into the combination of TTFields with established standard of care approaches such as temozolomide [7, 27] , bevacizumab [8, 32, 33] , and ionizing radiation [34] . The novel combination of TTFields with Withaferin A commands interest because of their synergistic interaction against human-derived glioma cell cultures. However, more preclinical and clinical work will be necessary to establish if the synergistic interaction between the treatments of TTFields and Withaferin A exists in murine models and in GBM patients respectively. Unfortunately, such deeper investigations are hampered by the current unavailability of a functional device to produce TTFields on preclinical, murine and orthotopic models of GBM.
Unlike TTFields, Withaferin A and related withanolides have yet to be approved by the FDA as anti-cancer agents. However, withanolides are effective against different cell culture strains of cancers [35] as well as in numerous preclinical models of murine and human cancer xenografts [36] , including human GBM [11] . Such investigations have also included toxicity studies in preclinical models [37, 38] and in clinical subjects [39, 40] . In general, these studies showed good tolerability to oral doses of either purified Withaferin A or Withania extracts that contain withanolides with minimal side effects Future preclinical and clinical investigations should include investigating the impact of metabolism on efficacy of Withaferin A [35] . The addition of such studies would likely bring approval of Withaferin A as an agent against cancer.
In the set-up of our studies we could not entirely separate the effects of heat generation and alternating electric fields on glioma cell viability. Nevertheless, in a rabbit study of TTFields in vivo, tumors treated for 21 days with sham electrodes heated to mimic temperatures generated by the TTFields (38-39.9 °C) increased in volume by a factor of 70 from baseline, whereas tumors treated with TTFields grew by a factor of 34 from baseline [25] . We showed that there was no difference in U87-MG cell growth for 8 days between temperatures of 37 and 39 °C (Supplemental Figure S3 C) . Finally, hyperthermia, used to treat malignant gliomas either as a single treatment or in combination with radiotherapy [41] , is effective between 42 and 43 °C, i.e., beyond the hyperthermic conditions explored in our experiments. These reports, in aggregate, would suggest that synergistic effects reported in this study are due to TTField and Withaferin A and not confounded by the presence of heat generation.
Another promising avenue of treatment is immunotherapy against glioblastomas [42] . Withaferin A is a steroid that has been shown to inhibit T cell-mediated immune response [43] . On the other hand, the scientific literature indicates that Withaferin A can display both immuno-inhibitory and immuno-stimulatory properties [35] . TTFields can affect T cells by partially inhibiting proliferation; however, TTFields do not impair any pivotal functional properties of the surviving T cells [44] . In addition, the application of TTFields on MDA-MB-231 breast cancer cells prompted the line to express immune stimulatory stress marker proteins such as calreticulin and HSP70 as well as the secretion of HMGB1 [45] . Thus currently, the impact of combination therapy by TTFields and Withaferin A on the immune system (and consequently on immunotherapy) is unknown. A beneficial impact will most likely depend upon In summary, the combination of Withaferin A with TTFields represents a novel approach to treat GBM. Given the aggressiveness of the disease as well as the paucity of the diagnostic and therapeutic tools arrayed against GBM, such a unique approach is worthy of further pursuit.
